Pioneering lymphatic targeting to address the limitations of current oncology therapies.
Propella is employing a platform of medicinal chemistry and lymphatic targeting to create best-in-class oncology drugs starting from known actives that have validated mechanisms of action (MOAs) and biological targets. Lymphatic targeting enables therapies to be delivered directly to targeted tissues via the lymphatic system thereby bypassing first-pass liver effects. This approach provides increased bioavailability to tissues of interest including lymph nodes and bone metastatic sites, increased pharmacological activity, reduced liver effects, and an improved safety margin. The company’s lead drug candidate, PRL-02, is a potential best-in-class CYP17 lyase inhibitor and as such is an androgen receptor (AR) pathway-directed therapy for the treatment of advanced prostate cancer.
“Propella” comes from the combination of “propel”, to drive, push and cause forward or upward motion, and “Capella”, a first magnitude star used in navigation. Capella consists of a primary pair of stars, which enhance, illuminate and strengthen each other, ultimately appearing as one.